Fenwick represented DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology, in its $80 million Series C financing.
The round was led by RA Capital Management with participation from new investors, including Eventide Asset Management, New Leaf Venture Partners, Soleus Capital, Driehaus Capital Management, Osage University Partners and Asymmetry Capital Management. Existing investors Northpond Ventures, Sands Capital, Sanofi Ventures, Alexandria Venture Investments, Altitude Life Science Ventures and Agent Capital also participated.
Proceeds from the financing will support the progression of DiCE’s oral IL-17 antagonist into clinical trials, as well as enable the advancement and expansion of its preclinical portfolio of additional protein-protein-interface antagonists. More information can be obtained from DiCE’s announcement.
The Fenwick transaction team was led by corporate partner Matthew Rossiter and included partner Thomas Kang, associate Noah Johnson, and law clerk Riddhi Adhikari; and tax partner William Skinner.